Home›Trial›NCT07195916
NCT07195916Phase 1RECRUITING

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Study Summary

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Conditions
Solid TumorsHematologic Malignancies
Interventions / Drugs
INCA036873
View on ClinicalTrials.gov ↗
Sponsor
INCY
Incyte Corporation
Oncology
F35/100
Study Details
Enrollment280 participants
Primary Completion—
Lead SponsorIncyte Corporation
Data Retrieved2026-04-11 02:55:29.647897+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 280 participants
Sponsor Catalyst Profile

Incyte Corporation (INCY) is the sponsoring company for this trial. BiotechSign currently grades this company F (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

INCY Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.